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4Introduction
The European Commission aims to enhance European 
competitiveness and tackle societal challenges through research 
and innovation (European Innovation Partnerships (EIP)). 
Active and Healthy Ageing (AHA) is a major health and 
societal challenge in all European countries, and an area with 
considerable potential for European leadership. An initiative 
was therefore launched by the EIP on AHA to accomplish a 
triple win (1):
• Enabling citizens to lead healthy, active and independent 
lives while ageing.
• Improving the sustainability and efficiency of social and 
health care systems.
• Boosting and improving the competitiveness of the markets 
for innovative products and services responding to the ageing 
challenge.
The EIP on AHA programme framework defined priority 
areas of work translated into six specific Action Groups (AG). 
Over 500 commitments were submitted from organisations 
(Table 1) and 32 Reference Sites were recognised in July 2013 
as excellence sites for innovation in AHA. 
Aim of the Task Force on synergies
The EIP on AHA requires a multidimensional and 
multidisciplinary approach. After three years of collaboration 
and activities, many achievements have been obtained. 
However, AGs have often worked in silos. Now that AGs have 
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Table 1
Terminology used in the paper
Organisations can participate in the EIP on AHA using:
•  Individual commitments: Individual task of an AG.
•  Collaborative work: Project agreed by an AG and carried out by several organisations.  
Results are tangible outcomes from commitments and/or collaborative work (e.g. a report, a completed pilot study, a guideline, etc.). They have to 
be specific, measurable, achievable and time-bound. 
Synergies (defined by the Synergy TF in coordination with AGs): Commitments and/or collaborative work with cross-cutting interest and rele-
vance to several AGs. They were established using a concerted approach. A synergy should be in line with the individual AG’s Renovated Action 
Plan. 
Collaborative work and Synergies can be managed on a voluntary basis following the objectives set or in a more agile way using SPRINTS that 
are proposed using a specific template with defined short-term results reported every 6 months.  In software product development, a sprint is a set 
period of time during which specific work has to be completed (http://searchsoftwarequality.techtarget.com/definition/Scrum-sprint).
5matured, more attention can be given to collaboration across 
AGs for topics with a shared interest. 
In the next phase of the EIP on AHA programme, synergies 
will be initiated for a practical, action-oriented contribution to 
a common framework to further strengthen the EIP on AHA 
triple win.
More specifically, the aims of the TF are to:
1- Outline the methodology and current status of the EIP on 
AHA synergies.  
2- Align with the AG Renovated Action Plan (RAP).
3- Evaluate the progress, results and impacts of the synergies 
with MAFEIP (Monitoring and Assessment Framework for 
the EIP on AHA) (2, 3).
4- Support the existing EIP on AHA Scaling Up Strategy 
(https://ec.europa.eu/research/innovation-union/pdf/active-
healthy-ageing/scaling_up_strategy.pdf)
Methodology used by the Task Force to develop synergies
Selection of task force members
A TF was set up to identify synergies, and to describe and 
evaluate them. Initially, each AG selected at least 2 members. 
Members of the PROEIPAHA Coordination and Support 
Action and the AG promoters were also invited to participate in 
the TF. .
Template to develop proposals for synergies
Synergies were based on a common 4-page template that was 
unanimously agreed upon by all the TF members (Table 2).
Assessment of proposals
A transparent methodology was developed to evaluate the 
synergies on relevance, quality and applicability. The templates 
were evaluated by two members from each AG based on a set 
of criteria checked through Survey Monkey (Figure 1) (www.
surveymonkey.com). All proposals with a threshold mean 
level of 6/10 or above for all the 9 criteria were approved (a 
unanimous decision was required). The inter-rater variance 
was low between assessments. Proposals that did not reach the 
threshold level were revised and further approved. Finally, 8 
proposals were accepted and one was withdrawn.
Figure 1
Survey Monkey evaluation of proposed synergies
Table 2
Template used to submit synergies
1. Title of the proposal
2. Leading organisation
3. Supporting organisations
4. Action groups
    A1  A2  A3  B3  C2  D4
AG initiating the proposal      
AG already involved      
AG to be contacted      
5. Rationale for the synergy
6. Achievements of the EIP on AHA AG
7. Objectives
• General objectives
• Specific objectives
8. Concrete plan
9. SPRINTS (2016-2017)
N°       Name       AG       Starting date       Delivery date       Geographical distribution       Results
S1      
S2      
10. Associated EU programmes
11. Alignment with the EIP on AHA objectives
12. Resources currently available for the projects
13. Expected impact
6Type of synergies
Two types of complementary cross-cutting synergies were 
submitted (Figure 2): 
•  Synergies considered overarching as they address topics that 
are relevant for most or all AGs
• Cross-cutting synergies focussing on a current AG activity 
which will be deployed to other AGs 
The 8 synergies are detailed in the online supplement.
Figure 2
Synergies of the EIP on AHA  
Activities of the Proposed Synergies 
Overarching synergies 
Information technology and adherence in an ageing 
population with chronic  diseases and appropriate 
polypharmacy
Leading AG: A1
Rationale: Multimorbidity leads to multiple medications 
(polypharmacy), increasing the risk of drug interactions, 
poor treatment adherence and adverse drug reactions (ADR). 
Failure to adhere to medical treatment increases therapeutic 
failure (5), causes unnecessary complications (6) and increases 
hospitalization and healthcare costs (7).  
General objectives: To increase the adherence to treatment 
of seniors with chronic diseases and polypharmacy (i) assessing 
the role of ICT-based solutions and (ii) implementing tailored 
ICT- based interventions.
Specific objectives 
1- To study if the application of progressive ICT systems 
that connect patients with health care professionals can 
boost the adherence of seniors in long-term therapies and 
polypharmacy, also considering pharmacists. Results from 
running pilots in the EU will be used for deployment.  
2- To study the role of integrated information systems 
connecting all stakeholders (e.g. patients, family members, 
health and social carers, and members of municipalities, 
hospitals, social care entities). Results from a running pilot in 
the EU will be used for deployment.
3- To review best practices and available literature to assess 
whether ICT-based applications that support training, 
patient empowerment and social interactions can change the 
behaviour and increase the adherence of seniors to treatment.
4- To use the lessons learnt in Italy by a National plan for 
Adherence involving the Italian Medicines Agency 
(AIFA), the national federation of general practitionners 
(FIMMG), Geriatrics and Patients associations (in particular 
Federanziani) and universities. The barriers and results of 
this network can be used to develop or scale up innovative 
approaches at the EU level.
Contribution to the Scaling Up Strategy of the EIP on AHA: 
The study intends to exploit results from many EU countries.  
Expected Outcomes / Contribution to MAFEIP
1- Impact on QOL: Increased adherence of seniors to medical 
plans will promote healthier ageing and QOL while reducing 
complications. 
2- Increased adherence to medical plans will impact the 
sustainability of the healthcare systems. Specific metrics 
used in the study are currently being defined.
3- Impact on Economic, Growth and Jobs for both the 
pharmaceutical industry and in the area of home care 
technologies and services. Opportunities for the development 
and production of new advanced products are expected to be 
generated leading to the requirement of more qualified jobs 
for the new services.      
Citizen and patient empowerment
Leading AG: B3, Action Area 6
Rationale: Nearly all the Action Plans launched in 2012 refer 
to patient or citizen empowerment. An active involvement of 
patients in their interaction with health and social professionals 
increases care effectiveness and efficiency. Citizen 
empowerment and the facilitating role of ICT are key topics 
in the EU H2020 programme. However, the work done in the 
EIP on AHA has shown  divergent understanding of citizen 
empowerment, defined in terms of education, joint decision-
making and self-management. Tools such as measures of health 
literacy and the capacity of individuals or groups for self-
management in chronic conditions would be of considerable 
value in reducing social inequalities.
General objectives: To achieve a common understanding of 
citizen and patient empowerment, and to implement and scale-
up good practices. 
Specific objectives
1- Develop a consensus view of citizen and patient 
empowerment across the different AGs.
72- Share and align citizen empowerment-related activities 
within and across AGs.
3- Formulate a set of broad holistic actions, based on a common 
understanding, to facilitate the scaling-up of good and 
effective practices via transverse (Synergies TF) as well as 
vertical processes (AGs) that support the overall objectives 
of the EIP on AHA.
4- Scale-up good practices and disseminate knowledge via the 
Synergies TF, the AGs, the Reference Sites and relevant EU 
and national initiatives.
Contribution to the Scaling Up Strategy of the EIP on AHA: 
How many regions?
All EIP on AHA partners and regions will be involved in this 
synergy. Additionally, all Reference Sites in the Reference Site 
Collaborative Network (RSCN) will be invited to participate. 
Expected Outcomes / Contribution to MAFEIP: “Patients 
with chronic conditions are often referred to as the most under-
used resource in the health system while patient-centred care 
models have demonstrated better quality of care as well as 
potential long-term cost-efficiencies. Too many patients are 
still struggling to get the support they need to become equal 
partners in care. To make real progress, we need to make 
patient empowerment a priority, starting with the development 
of an EU-wide strategy and action plan” 
1. Impact on QOL with an adequate social network and 
sufficient empowerment (8-11).
2. Empowerment of patients and citizens is seen as a key aspect 
in maintaining health and care systems sustainable (12, 13).
3. Empowered citizens are more self-sustaining and 
economically productive (14, 15). 
Masters of AHA educating seniors, health and social carers 
and entrepreneurs 
Leading AG: A2
Rationale: Integrated, interdisciplinary and inter-professional 
education for all stakeholders is needed to tackle the interrelated 
syndrome of frailty, malnutrition, falls, chronic diseases, and 
their social consequences. 
General objectives: Development of an innovative, dynamic 
and sustainable care system for AHA by capacity building 
through senior/patient-centred, multidisciplinary and inter-
professional educational programmes aimed at patients, patient 
caregivers (both formal and informal), health and social carers, 
administrators and entrepreneurs. 
Specific objectives:
1- Multi-professional education to improve the links between 
all stakeholders through better understanding of the 
knowledge and competencies of each stakeholder.
2- Master of Gerontology and Geriatrics: To develop dynamic 
and sustainable care systems that will encompass inter-
disciplinary, inter-professional education (IPE) and learning 
(IPL) including RRI business models.  
3- Best evidence holistic perspective to bring together research, 
practice, policies and market by courses in medical, nursing, 
pharmacy, social, behavioural, psychological, economic 
physiological, management service aspects related to 
the prevention and management of ageing and using the 
innovation loop of planning up-scaling strategies. 
4- To promote AHA as well as the empowerment of self-care 
and (care) independency, by placing the older person at the 
centre of care.  
Table 3
Examples of Masters of Gerontology and Geriatrics in Europe
Country Region or Reference site Website Title Language
Austria Graz Medical University Master of Gerontology and Geria-
trics
English
Austria Medical Doctors’ Associa-
tion Austria
http://www.aerztekammer.
at/veranstaltungen
Postgraduate Training Course for 
Medical Doctors in Geriatric Medi-
cine 
German
Belgium European Academy of 
Aging (EAMA)
http://eama.eu Leadership programme for academic 
geriatricians
English
France Languedoc Roussillon 
(16-18)
http://reseau-idefi-2015.
strikingly.com
Trans Innov Longévité: Trans-disci-
plinary, multisectoral, private-public 
partnership to train and coach on 
frailty, ageing and independent living
French
Portugal Ageing@Coimbra http://www.ed.uc.pt/educ/
cursoid=96
Distance Learning Course for Care 
Providers and the general public
Portuguese
UK British Geriatric Society http://www.bgs.org Spring Postgraduate training course, 
geriatric medicine, Edinburgh 
Scotland 
English
UK University of Oxford http://www.oxford.edu. Onsite training courses English
8Contribution to the Scaling Up Strategy of the EIP on AHA: 
The programme will be started at the Medical University of 
Graz, Austria by a well-defined Master of Gerontology and 
Geriatrics. The course will be in English and the teachers and 
participants will be from different institutions in Europe. This 
programme will be a pilot for other European programmes. The 
multi-professional approach will be developed in collaboration 
with the European Interdisciplinary Council on Ageing (EICA) 
gathering professionals from all disciplines interested in 
AHA and also implementing knowledge transfer to political, 
economic and lay stakeholders in the field.
Regions to be included: Regions will have a role for 
contributors, sharing their experiences and best practices, as 
well as for learners. Some examples of education programmes 
carried out in other regions are given in Table 3.
Efficient running of the programme: A scientific advisory 
committee is elaborating a landscape of educational events 
(homepage of the Medical University of Graz/Austria). 
Experts in the field of AHA will set up quality standards for 
live or long-distance educational events in the field of AHA 
(e-learning). The committee is composed of members from all 
stakeholders involved in AHA across Europe. The committee 
will work closely with the members of the RRI framework 
to ensure evidence-based multi-professional education and to 
deliver educational research results.  
Expected Outcomes / Contribution to MAFEIP
1-  Impact on the QOL of seniors
2- Ensure health promotion, literacy, engagement and 
empowerment of senior citizens in aspects related to 
adopting interventions and life styles that promote active 
and health ageing (e.g. acceptance of evidence-based 
interventions, behavioural changes towards AHA).
3- Impact on the Sustainability of Health and Care Systems
4- Impact on Economic, Growth and Jobs 
AHA in the framework of Responsible Research and 
Innovation (RRI)
Leading AG: D4
Rationale: Responsible Research and Innovation (RRI) is 
an approach anticipating and assessing potential implications 
and societal expectations of research and innovation (19, 20). 
RRI allows all stakeholders involved in research and innovation 
(i) to obtain relevant knowledge on the consequences of the 
outcomes of their actions, (ii) to effectively evaluate outcomes 
in terms of societal needs and moral values and (iii) to use these 
considerations for the design and development of new research, 
products and services (19). The concept in Europe considers 
eight key areas (21) that should be included in the dialogue 
among the different AGs of the EIP on AHA: Governance, 
Public Engagement, Gender Equality, Science Education, Open 
Science/Open access, Ethics, Sustainability and Social Justice/
Inclusion.
General objectives: To provide a roadmap of actions to be 
undertaken to promote RRI in AHA.
Specific objectives:
1- To identify the current state of the actions and initiatives 
related to the concept of RRI in the AHA framework and the 
concrete contribution of the partners and AGs. 
2- To create a group of partners interested in working in this 
area and to identfy the most urgent actions and the plan of 
execution for RRI in AHA for the following years. 
3- To analyse the work done in AHA in terms of RRI in the 
framework of the EIP on AHA and other related networks.
4- To provide a roadmap of urgent actions to be undertaken in 
RRI for AHA.
Contribution to the Scaling Up Strategy of the EIP on AHA: 
The synergy considers the engagement of higher numbers 
and more diverse stakeholders involved in the chain supply of 
active and healthy ageing products and services.  These would 
include grass-root stakeholders (at local and regional level) 
with no possibility to join the EIP on AHA in Brussels due 
to economic, linguistic or time limitations and would enable 
the promotion of a richer dialogue and collaboration. The D4 
partners/coordinators suggested the consideration of new agents 
as actors participating in AHA promotion at early stages and 
other actors supporting innovative ways of promoting active 
seniors i.e., schools, volunteers, touristic operators, social 
entrepreneurs.
Expected Outcomes / Contribution to MAFEIP: Integration 
of the concept of RRI to AHA is lacking. This synergy will 
create a baseline for future development and the integration of 
this trend in a structured and holistic way with the support of 
relevant stakeholders.
Maturity Model for Integrated Care
Leading AG: B3, Action Area 7
Rationale: Scaling up of EIP on AHA good practices in 
integrated care to EU regions is essential to reduce health, 
gender and social inequities in Europe.  
General objectives: The B3 AG has developed  the B3 
Maturity Model to assist  regions with their efforts to deploy 
integrated care in Europe in order (i) to reveal the strengths 
and weaknesses of European regions, (ii) to match those with 
similar problems and environments to work together and (iii) to 
help regions scale up their activities.
Specific objectives
1. To share learning and expertise gained during  development 
of the B3 Maturity Model 
2. To adjust the Maturity Model to address challenges of ageing 
in Europe such as adherence, frailty, falls prevention and 
assisted living solutions.
3. To develop self-assessment tool(s) to assess the readiness of 
regions in the  implementation of solutions for AHA.
4. To test and validate the Maturity Model as a tool for 
supporting the scaling up and replication of innovative 
solutions; and facilitating  knowledge transfer and exchange 
of good practices in Europe.
9Contribution to the Scaling Up Strategy of the EIP on AHA: 
Aiming to conduct self-assessment in 8 regions, with twinning 
and coaching activities facilitated by B3 regions. 
Expected Outcomes / Contribution to MAFEIP 
1- Scaling up effective integrated care will improve the quality 
of care, health and wellbeing of citizens.
2- Positioning of European regions in terms of strengths 
and weaknesses will inform national, regional and local 
authorities about their “future direction of travel” – quick 
and systematic identification of areas that need attention to 
achieve improvement in AHA solutions.
3- Integration of health and care will lead to new roles and 
competencies for the workforce, and will generate 
opportunities for growth through scaling up of effective 
models of care / solutions.
Cross-cutting synergies focussed on an Action Group
Falls prevention and injuries: a grand societal challenge
Leading AG: A2
Rationale: Falls represent a major cause of burden and 
death in seniors (22). Approximately 30% of falls result in 
an injury that requires medical attention. Fractures occur in 
approximately 5% of falls and hip fractures in 1% (23-26). 
Falls-related injuries account for over 5% of the medical 
expenditures in seniors. Falls are the third leading cause of 
years lived with disability.
General objectives: To scale up a falls prevention and 
injuries initiative from local pilot studies to a practical and 
feasible pan-European programme including all stakeholders.
Specific objectives
1- Enable macro-, meso- and micro-level analysis including 
governance and policy-making based on screening, 
prevention, rehabilitation and monitoring, as well as an 
integration with the Silver Economy, and related to WHO’s 
consultation on Global Strategy and Action Plan on Ageing 
and Health.
2- Engage regional and municipal levels in fall prevention 
campaigns, thereby enabling and promoting early frailty and 
fall risk assessment, and identifying frail and faller profiles.
3- Anticipate and identify the data analytic scope for health 
outcome studies in order to utilize the infrastructure and 
support the widest possible variety of health and social 
studies, including support for further methods and care 
service developments related to frailty and fall injury 
intervention and prevention.
4- Raise awareness and promote behavioural change among 
citizens in the prevention of frailty and fall injuries including 
post-operative interventions.
5- Understand falls-risk-increasing drugs and frailty.
6- Provision of specific smart home and smart building 
oriented ICT solutions viewed from a socio-economic Key 
Performance Index perspective.
Contribution to the Scaling Up Strategy of the EIP on 
AHA: How many regions?: Five to ten demonstrator regions 
are proposed, including Austria/Steiermark, Finland, France/
Languedoc-Roussillon, Ireland, Scotland, Spain (Region of 
Madrid-Getafe University Hospital and Basque country). 
Austria, Finland and France have agreed. Discussions are 
ongoing with others.
Expected Outcomes / Contribution to MAFEIP: Scaling-
up of good practices with an extended MAFEIP monitoring 
framework (2, 3) including socio-economic and macro-
economic aspects.
1- Fall risk assessment is often embedded into a broader scope 
of geriatric assessment, e.g. including cognitive and non-
cognitive aspects of dementia, activities of daily life (ADL), 
QOL, depression and nutrition. EQ5D is often used but 
is not sufficient for a broader scope of assessment. Finer 
granularity is needed.
2- Pathways and care processes are important ingredients in 
sustainability. This process of sustainability is discussed 
within the AG.
3- Impact on Growth and Jobs: The AG is discussing the whole 
ecosystem, from both topdown and bottom up approaches.
Impact of the Community-based Programme on Frailty 
Prevention and frailty Mitigation (ICP – FPM)
Leading AG: A3
Rationale: Prevention, screening, early identification and 
diagnosis of frailty and functional decline are closely related 
with the integrated care of chronic diseases. They operate 
primarily in the community, requiring the integration of health 
(primary, secondary) and social care to deliver screening, 
targeted assessment (e.g. Comprehensive Geriatric Assessment) 
and evidence-based, cost effective and tailored interventions 
(27-30). This comprehensive approach aims to prevent 
disability, recurrent hospitalizations, institutionalization and 
related heath-social care costs (27, 31, 32). Interventions must 
integrate health care and a supportive social environment for the 
patient and caregiver (33, 34). Women may be at higher rates of 
physical and cognitive frailty and interventions must be gender 
and cultural sensitive. 
General Objective: 
To set up a public health approach 
• To prevent, identify and manage frailty in community 
dwelling older adults, to be validated in different EU 
member states, 
• To identify the factors that can be targeted in order to, delay 
or postpone further decline and disability.
Specific objectives 
1. To join systematic frailty assessment with good practices in 
frailty prevention and management, by counteracting social 
isolation, and improving nutrition, adherence to therapy and 
physical activity. 
2. To promote the continuum of care by integrating social and 
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health care at primary,secondary and tertiary levels.
3. To assess the impact of this public health model to manage 
frailty in the community in terms of cost effectiveness, use of 
health services, acceptance by citizens and patients’ QOL.
4. To test the relation between a set of indicators and the 
prevalence of frailty. 
5. To exploit existing ICT-supported assessment and 
intervention tools. 
6. To describe caregiver network’s weaknesses and strengths, 
and implement strategies to maintain, supplement and 
improve this network.
Contribution to the Scaling Up Strategy of the EIP on 
AHA: The proposal includes projects already developed in 
six European countries and is going to include organizations 
based in two more countries. The objective of the proposal is to 
represent all European Regions.
Expected Outcomes / Contribution to MAFEIP  
1- Community-based programmes should reduce mortality, 
hospitalization and institutionalization rates in order to 
improve QOL in the elderly.
2- The proposal will assess the capacity of different 
interventions aimed to strengthen  community-based health 
and social care programmes and reduce the work load on 
hospitals and residential Long Term Care services that are 
much more expensive.
3- Impact on Growth and Jobs: strengthening community-based 
services needs an increased number of dedicated personnel 
with potential benefit for the employment levels.
4- Some markers of the availability of socio-economic 
resources will be also assessed for their impact on frailty 
because of their strong relation with mortality rate and an 
increased use of health resources such as hospitalization and 
institutionalizations.
Multimorbidity of chronic respiratory diseases in seniors: an 
under-recognised societal problem (B3)
Leading AG: B3, Action Area 5
Rationale: Chronic Respiratory Diseases (CRD) are major 
chronic diseases. Some occur early in life (e.g. asthma-rhinitis) 
and persist throughout life (35, 36). COPD is associated with 
frailty in seniors (multimorbidity, polymedication). CRDs 
are intertwined with ageing and negatively impact AHA. The 
prevention and control of CRD in the ageing population is vital. 
Integrated care pathways have been set for CRDs (AIRWAYS 
ICPs) in the B3 AG (37-39).
General objectives: To better understand, prevent, detect 
and manage CRDs in elderly people, and to assess the impact 
of their socio-economic and health services utilization. Simple 
ICT tools allowing individualised medication should be 
developed. To raise the awareness of the role of CRDs in 
the elderly, and advocate for a European strategy, in order to 
support the scaling up of regional interventions. A stepwise 
action plan is proposed including scientific societies and the 
involvement of patient’s organisations.
Specific objectives 
1- Promotion of AHA: Fit at work with rhinitis: Rhinitis 
impacts work productivity more than diabetes, hypertension 
or asthma. In Europe, work productivity costs due to rhinitis 
are over 30 B¤ yearly. The control of rhinitis by treatment 
improves work productivity (40). This project includes care 
pathways and should be a pilot for other common chronic 
diseases.
2- Ageing well with rare paediatric diseases (e.g. cystic fibrosis 
(CF) or bronchopulmonary dysplasia): The transition 
between paediatrics, adult medicine and geriatrics is a key 
issue for AHA in this severe genetic disease. The model of 
CF can be deployed to other rare diseases (41).
3- Understanding, promoting health and controlling CRDs 
across the life cycle for AHA (36) following the Polish (11, 
42) and Cyprus priorities of the EU Council (43).
4- Understanding CRDs in elderly people: Care pathways 
for airway diseases (rhinitis, asthma and COPD) and 
their multimorbidities in elderly people need to identify 
prioritized questions and use ICT tools (44, 45). Public 
health initiatives are needed for the early identification of 
those presenting in a pharmacy to purchase treatment.
5- Multimorbidity in CRDs. To describe the clinical profile of 
patients with CRDs, the patterns of multimorbidity, and the 
use of health services in this group of patients based on the 
EpiChron cohort study (1.3M inhabitants).
6- Integrated care pathways for rhinitis across the life cycle 
and remote monitoring with a specific focus on seniors (44, 
45).
7- Interactions between chronic respiratory diseases and frailty
8- Polymedication: In CRDs, and particularly in COPD, 
patient adherence is far from perfect. Most often, patients 
discontinue their treatment very soon after its initiation. 
Polymedication has profound medical and economical 
consequences.
9- Societal problems in CRDs will be initially tackled with the 
CARSAT (Caisse d’Assurance Retraite et Santé au Travail, 
Social Security, France) (4, 18) and scaled up to EU regions 
using the ICT tool on AHA (46-48).
10- Scaling up strategy, education, coaching and training 
(EUFOREA).
Contribution to the Scaling Up Strategy of the EIP on AHA: 
AIRWAYS ICPs is currently deployed in 25 EU countries with 
national coordinations.
Expected Outcomes / Contribution to MAFEIP
1- All CRDs impact QOL severely across the life cycle. 
AIRWAYS ICPs is likely to have a major impact in seniors.
2- Novel care pathways including self-care, health and social 
carers that are patient-centered are required and represent 
one of the major objectives of AIRWAYS ICPs. Better 
knowledge of the patterns of multimorbidity in CRDs and 
the characteristics of health care use.
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3- Fit at work with rhinitis will have a major impact on 
economy.
Embedding synergies in EIP on AHA Reference Sites
Synergies have been built among EIP on AHA Reference 
Sites as examples of comprehensive, innovation-based 
approaches to AHA. EIP on AHA Reference Sites are coalitions 
of regions, cities, integrated hospitals or care organisations 
able to show a concrete impact of innovative practices, which 
could be transferred to other European contexts. A total of 32 
Reference Sites have been awarded (1).
Reference Sites conscious of the need for synergies and a 
collaborative approach to address health and care challenges of 
an ageing population expressed the common will to establish a 
Collaborative Network to facilitate joint reflection and action 
in sharing and transferring best practice in the development and 
scaling up of health and care strategies, policies and service 
delivery models.  
The interregional  Reference Si te  Col laborat ive 
Network (RSCN) includes References Sites recognised by 
the Commission as well as Regions intending to apply for 
Reference Site status (candidate Reference Sites). Its main goal 
is to improve health and care through an active cooperation, 
contributing to the general debate with the EU institutions, 
in order to optimise the possibilities for sharing a strong, 
sustainable health and care system for all, while respecting 
the different competences and responsibilities in the direct 
organisation of the health and care services of the Member 
States and Regions. 
Support for the EIP on AHA Scaling up strategy 
The Scaling Up Strategy will follow the 5-step approach 
that has been proposed by the EIP on AHA and that has 
already been applied to AIRWAYS ICPs ((https://ec.europa.eu/
research/innovation-union/pdf/active-healthy-ageing/scaling_
up_strategy.pdf, Bousquet et al, submitted). 
An up-scaling strategy is multidimensional where accurate, 
appropriate and complete execution of each step is necessary 
to enable rigorous and systematic fulfilment of subsequent 
steps in the up-scaling process. As an example, up-scaling the 
IKINÄ (THL National Falls Prevention Initiative) guideline 
for fall prevention by THL (Terveyden ja Hyvinvoinnin Laitos, 
National Institute for Health and Welfare, Finland) in Finland 
(49) may be proposed. WHO’s ExpandNet guides (50) to 
up-scaling may provide potential additions to the Scaling-up 
Strategy of the EIP on AHA’s. 
The dissemination was proposed to be carried out using 
the same model as previous B3 AG and/or AIRWAYS ICPs 
meetings (36, 39, 43, 46-48, 51-55).
Monitoring of activities carried out within the synergies
MAFEIP
Monitoring the activities carried out within the EIP on AHA 
needs a flexible and consistent approach to estimate health and 
economic impacts across interventions and commitments. A 
generic and flexible web-based monitoring and assessment tool 
has been developed. The MAFEIP tool estimates health and 
economic outcomes in terms of incremental changes in Quality 
Adjusted Life Years (QALYs) as well as health and social care 
utilisation. The MAFEIP-tool can provide an early assessment 
of the likelihood that interventions will achieve the anticipated 
impact. It can also to identify what drives the effectiveness or 
efficiency of interventions to guide further refinement, design 
upgrades and evaluation (2, 3).
AHA operative questionnaire
A core operational definition of AHA is needed to conduct 
comparisons (56). A conceptual AHA framework proposed 
by the RSCN includes several items such as functioning ((the 
following bracket needs to be closed but I don’t know where)) 
(individual capability and underlying body systems, well-
being, activities and participation, and diseases (including 
non-communicable diseases, frailty, mental and oral health 
disorders) (46, 47). The instruments include core and optional 
domains/instruments depending on the needs and questions 
(48). A major common domain is function as measured by the 
World Health Organization Disability Assessment Schedule 2.0 
(WHODAS 2.0) that can be used across all diseases and healthy 
individuals. It covers many of the AHA dimensions proposed 
by the RSCN. However, WHODAS-2.0 does not include 
all dimensions proposed for AHA assessment. The second 
common domain is Health-Related QOL (HRQL). EQ-5D is 
one of the QALY measurements and the AHA questionnaire 
is therefore interoperable with MAFEIP. The instrument is 
translated and culturally validated for most EU countries and 
will be digitalized in the first quarter of 2016. A report of the 
AHA questionnaire in the form of a spider diagramme will 
facilitate usual comparisons across individuals and groups of 
interest (56).
5-3- Other tools
Assessment scales, as information entities, are not often 
equipped with a rigorous typing of data. This disables the gap 
between logic and guidelines, not only in geriatric assessment 
(57)  but also within municipal and regional decision-
making in elderly care. Logic is, on the one hand, a carrier of 
information, and, on the other hand, it includes a mechanism 
for rigorous logical inference which underlies decision-
making. Gerontological conditions and circumstances are about 
information and knowledge, and gerontological data can be 
properly typed to open up possibilities e.g. for comparative 
studies and development of regional and national repositories 
involving gerontological data and information (58).
The information structure representation of nomenclatures 
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and classifications is also important. WHO classifications 
are logically lative (59). The reference classifications ICD 
(International Classification of Diseases) and ICF (International 
Classification of Functioning, Disability and Health) then 
appear in structured relation with each other. Similar 
transformations can be made for the derived and related 
classifications ICPC-2, ICECI, ISO9999, ATC/DDD and ICNP 
(60).
These information entities are inherently multivalent, 
and classifications like the ICF explicitly recognize this 
multivalence through introduction of its generic scale. This, in 
turn, requires the formal management of many-valuedness and 
uncertainty in a logical setting (49).
Conclusion 
AHA requires a multidimensional and multidisciplinary 
approach to allow people from multiple backgrounds to work 
together sharing a common language. The experience of 
different stakeholders working in a collaborative way producing 
concrete results in the different Action Groups sets a promising 
ground for the difficult challenge of scaling up good practices at 
European level.
The added value of working together requires identifying 
synergies not only between different good practices but also 
between different Action Groups results. To yield actual 
benefits, they have to be developed in concrete action plans 
that explain the rationale for the synergy, the participants, the 
objectives and a concrete plan with sprints.  
EIP AHA implementation can manage a limited number 
of synergy actions. To select them, a flexible but structured 
process, with a transparent evaluation methodology, had to 
be used. The success of the first call, with nine proposals 
submitted and evaluated, supports the viability of the approach 
chosen. Eight of the proposals were selected.
New stakeholders have to join and new proposals need to be 
implemented. To ensure the added value of the whole process, 
Actions have to be assessed according to their estimated health 
and economic outcomes as well as health and social care 
utilisation using MAFEIP and other tools.
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